- Bird Flu Virus May Survive Aging Process in Raw Milk Cheese
- Study Finds Organ Health May Predict Dementia, Cancer Later in Life
- First Patient Cured of Sickle Cell Anemia
- FDA Warns of Rising Injuries From Misuse of Laughing Gas
- 1 in 3 Children Now Suffer From Chronic Illness
- No Link Between COVID Vaccine During Pregnancy And Birth Defects, Study Says
- Death Risk Higher Among People With Arthritis And COPD
- Depression, Anxiety Common Among Chronic Pain Patients
- Steep Decline In Fertility Among U.S. Women Younger Than 30
- Time Of Day, Year Matters For Asthma Testing
Combination Antibiotic Zerbaxa Approved
The combination antibiotic Zerbaxa (ceftolozane/tazobactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated abdominal infections and complicated urinary tract infections.
The approval for abdominal infections was approved in combination with another drug, metronidazole, the agency said in news release. The approval for urinary tract infection includes infection of the kidney.
Zerbaxa is the fourth antibiotic to be FDA-approved in 2014, following approval of Dalvance (dalbavancin), Sivextro (tedizolid) and Orbactiv (oritavancin).
The drug’s label includes a warning about decreased effectiveness among people with kidney impairment, the FDA said. The most common side effects reported during clinical testing included nausea, diarrhea, headache and fever.
Zerbaxa is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.
More information
To learn more, visit the FDA.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.
Related
-
Common Vaginal Infection Should Be Treated as an STI, Study SaysA common vaginal infection that affects nearly 1 in...
- March 10, 2025
-
Hormone Therapy For Menopause Linked To Alzheimer’s HallmarkHormone replacement therapy during menopause appears to be linked...
- March 10, 2025
-
Sleepy Nurses Vulnerable To Common Cold, Other Infectious DiseasesSleep-deprived night shift nurses are at greater risk for...
- March 10, 2025
-
Cancer Screening Rates Rebound Post-PandemicPreventive screenings for cancer declined during the pandemic, with...
- March 6, 2025
